US-based Vertex Pharmaceuticals has axed plans to progress its acute pain drug, VX-993, into pivotal development after disappointing Phase II topline results. The NaV1.8 pain signal inhibitor, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback